Abstract
Long-acting injectable cabotegravir-rilpivirine (CAB/RPV-LA) is a promising treatment alternative for people with HIV (PWH) who face adherence challenges with oral antiretroviral therapy (ART). While its clinical efficacy is well-documented, cost-effectiveness data from real-world settings remain limited. To evaluate the incremental first-year cost and cost-effectiveness of CAB/RPV-LA versus standard of care (SoC) oral ART among PWH with adherence challenges, from the perspective of a healthcare payer. A cohort of 59 PWH initiating CAB/RPV-LA at Ward 86, a San Francisco-based clinic, was analyzed. Viral suppression (VS) rates and treatment costs were compared between CAB/RPV-LA and SoC ART. Cost-effectiveness was assessed using incremental cost per newly virally-suppressed PWH and net monetary benefit (NMB). Sensitivity analyses were performed to evaluate parameter uncertainty. CAB/RPV-LA achieved a VS rate of 92%, compared to an estimated 15% with SoC ART. The estimated first-year cost of CAB/RPV-LA delivery was $67,041 per patient versus $50,668 for SoC. The incremental cost per newly virally-suppressed PWH was $21,264. CAB/RPV-LA is the most cost-effective option at any willingness-to-pay above this level. The NMB was $243,721 suggesting favorable cost-effectiveness. Sensitivity analyses confirmed the robustness of these results. Initiating CAB/RPV-LA for PWH with viremia suggests highly favorable cost-effectiveness. Results are sensitive to the costs of antiretroviral drugs, but not to variations in personnel costs or rates of viral suppression within plausible input ranges.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call